Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7339250 | 1.00 | TSHR (0.46) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL9012682 | 1.00 | TSHR (0.46) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL28978626 | 0.93 | MAOB (0.41) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL28730834 | 0.89 | MEN1 (0.44) | MAOBCYP19A1ARKDM4EADORA3 | |
| SCHEMBL7259690 | 0.89 | MEN1 (0.44) | MAOBCYP19A1ARKDM4EADORA3 | |
| SCHEMBL28354123 | 0.88 | TSHR (0.43) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL2743656 | 0.88 | TSHR (0.43) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL15883776 | 0.86 | KDM4E (0.42) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL1331244 | 0.86 | KDM4E (0.42) | TSHRMAOBCYP19A1ARKDM4E | |
| SCHEMBL8019731 | 0.80 | ESR2 (0.56) | CYP19A1ADORA3HSD17B10ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113512300-A | High-extrusion-efficiency bamboo-based composite material containing carbon nano tubes and preparation method thereof | 浙江巧筑新材料科技有限公司 | 2021-10-19 | — | — | CN | claimed |
| CN-108467479-B | Toughened 2, 5-furandicarboxylic acid copolyester | 成都中科普瑞净化设备有限公司 | 2021-07-06 | — | — | CN | claimed |
| US-20090270299-A1 | Composition for removing protective layer in fabrication of MEMS and method for removing same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-29 | — | — | US | claimed |
| WO-2006052985-A1 | LACTONES AS NEW OXYGENATE FUEL ADDITIVES, FUELS BASED THEREON AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060096158-A1 | Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same | ROBINSON J M | 2006-05-11 | — | — | US | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0674233-B1 | Recording sheets | XEROX CORP (US) | 2000-05-24 | — | — | EP | claimed |
| US-6028224-A | Fluoxetine process from benzoylpropionic acid | SEPRACOR INC. (US) | 2000-02-22 | — | — | US | claimed |
| WO-1999067196-A1 | FLUOXETINE PROCESS FROM BENZOYLPROPIONIC ACID | SEPRACOR INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-5936124-A | Fluoxetine process from benzoylpropionic acid | SEPACOR INC. (US) | 1999-08-10 | — | — | US | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0692191-A1 | UTILIZATION OF PHENYL COMPOUNDS FOR THE CONTROL OF PHYTOPARASITE NEMATODES | UNIVERSIDAD DE LA LAGUNA (ES) | 1996-01-17 | — | — | EP | claimed |
| EP-0674233-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| US-5451458-A | Electrography | XEROX CORPORATION (US) | 1995-09-19 | — | — | US | claimed |
| EP-0240233-A1 | Derivatives of benzoquinonyl-phenyl alkanoic acid amide | SUNTORY LIMITED (JP) | 1987-10-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | TSHR 84/4885MAOB 423/4885CYP19A1 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.